I have posted this before. The similarities betwee
Post# of 36570
(Total Views: 460)
Posted On: 05/20/2020 9:30:09 PM
I have posted this before. The similarities between the companies is incredible as are the differences.
Both companies have been around for years. Neither CEO is a physician nor do they come from biotech backgrounds. Both are bulldogs in the way they attack a problem. Historically both CEO's are shareholder friendly although CYDY's CEO has been incredible the last couple of months between CC's, Proactive videos, interviews with Redchip etc. Also CYDY's chief scientists are way more publicly engaged than Generex's. Both companies are on the OTC but have aspirations of up listing SOON. GNBT was on the NAZ in the past. GNBT has a small-moderate float. CYDY's is moderate to largish. Both companies have cancer and virus platforms. Vaccine vs therapeutic treatment. Both companies have used shares in various ways to build the company as they have little revenue historically. Generex is aggressively building a robust holding company which will generate revenue to help fund further research programs including Type 1 and 2 diabetes and various cancer vaccines. They also are planning a MSO/HMO and have other lines of business such as surgical supplies for ortho. GNBT has signed agreements which will fund them for a year or so once they get their S-1 approved. CYDY is expecting financing soon probably from an investment bank which will allow them to start/continue trials for 20-30 indications including HIV/NASH etc plus various cancers. Both companies are working on government funding for Covid-19. Both have had there overall progress slowed considerably by covid and at the same time covid has presented an opportunity.
If you like projects, you chose the right two companies to invest in. I think both are fantastic opportunities. Neither are typical of what one usually sees with OTC listed stocks. Funding is the main problem for both.
Both companies have been around for years. Neither CEO is a physician nor do they come from biotech backgrounds. Both are bulldogs in the way they attack a problem. Historically both CEO's are shareholder friendly although CYDY's CEO has been incredible the last couple of months between CC's, Proactive videos, interviews with Redchip etc. Also CYDY's chief scientists are way more publicly engaged than Generex's. Both companies are on the OTC but have aspirations of up listing SOON. GNBT was on the NAZ in the past. GNBT has a small-moderate float. CYDY's is moderate to largish. Both companies have cancer and virus platforms. Vaccine vs therapeutic treatment. Both companies have used shares in various ways to build the company as they have little revenue historically. Generex is aggressively building a robust holding company which will generate revenue to help fund further research programs including Type 1 and 2 diabetes and various cancer vaccines. They also are planning a MSO/HMO and have other lines of business such as surgical supplies for ortho. GNBT has signed agreements which will fund them for a year or so once they get their S-1 approved. CYDY is expecting financing soon probably from an investment bank which will allow them to start/continue trials for 20-30 indications including HIV/NASH etc plus various cancers. Both companies are working on government funding for Covid-19. Both have had there overall progress slowed considerably by covid and at the same time covid has presented an opportunity.
If you like projects, you chose the right two companies to invest in. I think both are fantastic opportunities. Neither are typical of what one usually sees with OTC listed stocks. Funding is the main problem for both.
(5)
(0)